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SCIENTIFIC OPINION 
Scientific Opinion on the substantiation of a health claim related to 
DHA and contribution to normal brain development pursuant to Article 14 
of Regulation (EC) No 1924/2006
1
 
EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA)
2,3
 
European Food Safety Authority (EFSA), Parma, Italy 
ABSTRACT 
Following an application from DSM Nutritional Products, submitted for authorisation of a health claim pursuant 
to Article 14 of Regulation (EC) No 1924/2006 via the Competent Authority of the United Kingdom, the EFSA 
Panel on Dietetic Products, Nutrition and Allergies (NDA) was asked to deliver an opinion on the scientific 
substantiation of a health claim related to docosahexaenoic acid (DHA) and contribution to normal brain 
development. The Panel considers that DHA is sufficiently characterised, and that contribution to normal brain 
development is a beneficial physiological effect for infants and children. The Panel has already assessed a claim 
on DHA and maintenance of normal brain function with a favourable outcome. The Panel noted the well-
established role of DHA in brain function. The Panel considers that the role of DHA in normal brain function 
applies to all ages, including brain development in infants and children. The Panel also notes that the developing 
brain accumulates large amounts of DHA, particularly during the first two years of life, but also later and 
throughout childhood. The Panel concludes that a cause and effect relationship has been established between the 
consumption of DHA and contribution to normal brain development. The following wording reflects the 
scientific evidence: “DHA contributes to normal brain development”. In order to bear the claim, foods for older 
infants and young children below the age of 24 months should provide a daily intake of 100 mg DHA in one or 
more servings, while foods for children from 2 to 18 years should provide a daily intake of 250 mg DHA in one 
or more servings. 
© European Food Safety Authority, 2014 
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SUMMARY 
Following an application from DSM Nutritional Products, submitted for authorisation of a health 
claim pursuant to Article 14 of Regulation (EC) No 1924/2006, via the Competent Authority of the 
United Kingdom, the EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA) was asked to 
deliver an opinion on the scientific substantiation of a health claim related to docosahexaenoic acid 
(DHA) and contribution to normal brain development. 
The scope of the application was proposed to fall under a health claim referring to children’s 
development and health. 
The food that is the subject of the health claim is DHA (22:6 n-3), which is a well-characterised n-3 
long-chain fatty acid that can be quantified in foods by established methods. This evaluation applies 
to all sources of DHA in the specified amounts. The Panel considers that DHA is sufficiently 
characterised. 
The claimed effect proposed by the applicant is “contributes to brain development”. The target 
population proposed by the applicant is infants and children up to 18 years of age. The Panel 
considers that contribution to normal brain development is a beneficial physiological effect for infants 
and children. 
The Panel has already assessed a claim on DHA and maintenance of normal brain function with a 
favourable outcome. The target population was the general population. The Panel considered that 
DHA is the major structural lipid in brain tissue and the central nervous system, and that the 
membrane lipids of brain grey matter and the retina contain high concentrations of DHA. The Panel 
noted the well-established role of DHA in brain function. 
The Panel considers that the role of DHA in normal brain function applies to all ages, including brain 
development in infants and children. The Panel also notes that the developing brain accumulates large 
amounts of DHA, particularly during the first two years of life, but also later and throughout 
childhood. Dietary Reference Values for pre-formed DHA have been set for infants and children. 
The Panel concludes that a cause and effect relationship has been established between the 
consumption of DHA and contribution to normal brain development. 
The Panel considers that the following wording reflects the scientific evidence: “DHA contributes to 
normal brain development”. 
In order to bear the claim, foods for older infants (> 6 months of age) and young children below the 
age of 24 months should provide a daily intake of 100 mg DHA in one or more servings. Foods for 
children from 2 to 18 years should provide a daily intake of 250 mg DHA in one or more servings. 
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BACKGROUND 
Regulation (EC) No 1924/2006
4
 harmonises the provisions that relate to nutrition and health claims, 
and establishes rules governing the Community authorisation of health claims made on foods. As a 
rule, health claims are prohibited unless they comply with the general and specific requirements of 
this Regulation, are authorised in accordance with this Regulation, and are included in the lists of 
authorised claims provided for in Articles 13 and 14 thereof. In particular, Articles 14 to 17 of this 
Regulation lay down provisions for the authorisation and subsequent inclusion of reduction of disease 
risk claims and claims referring to children’s development and health in a Community list of 
permitted claims. 
According to Article 15 of this Regulation, an application for authorisation shall be submitted by the 
applicant to the national competent authority of a Member State, which will make the application and 
any supplementary information supplied by the applicant available to the European Food Safety 
Authority (EFSA). 
STEPS TAKEN BY EFSA 
 The application was received on 24/01/2014. 
 The scope of the application was proposed to fall under a health claim referring to children’s 
development and health. 
 On 04/04/2014, during the validation process of the application, EFSA sent a request to the 
applicant to provide missing information. 
 On 15/04/2014, EFSA received the missing information as submitted by the applicant. 
 The scientific evaluation procedure started on 24/04/2014. 
 During its meeting on 18/09/2014, the NDA Panel, having evaluated the data submitted, 
adopted an opinion on the scientific substantiation of a health claim related to DHA and 
contribution to normal brain development. 
TERMS OF REFERENCE 
EFSA is requested to evaluate the scientific data submitted by the applicant in accordance with 
Article 16 of Regulation (EC) No 1924/2006. On the basis of that evaluation, EFSA will issue an 
opinion on the scientific substantiation of a health claim related to: pre-formed DHA and contributes 
to brain development. 
EFSA DISCLAIMER 
The present opinion does not constitute, and cannot be construed as, an authorisation for the 
marketing of DHA, a positive assessment of its safety, nor a decision on whether DHA is, or is not, 
classified as a foodstuff. It should be noted that such an assessment is not foreseen in the framework 
of Regulation (EC) No 1924/2006. 
It should also be highlighted that the scope, the proposed wording of the claim, and the conditions of 
use as proposed by the applicant may be subject to changes, pending the outcome of the authorisation 
procedure foreseen in Article 17 of Regulation (EC) No 1924/2006. 
                                                     
4 Regulation (EC) No 1924/2006 of the European Parliament and of the Council of 20 December 2006 on nutrition and 
health claims made on foods. OJ L 404, 30.12.2006, p. 9–25. 
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INFORMATION PROVIDED BY THE APPLICANT 
Applicant’s name and address: DSM Nutritional Products, 6450 Dobbin Road, Columbia, 
MD 21405, USA. 
Food/constituent as stated by the applicant 
According to the applicant, the food that is the subject of the health claim is pre-formed DHA 
(docosahexaenoic acid; 22:6 n-3) from all sources. 
Health relationship as claimed by the applicant 
According to the applicant, the ingestion of DHA supports brain development. The applicant argues 
that the DHA content in the brain increases progressively throughout the developmental period from 
birth to 18 years of age and that it responds to diet. The applicant also claims that pre-formed DHA 
favourably influences neurodevelopmental outcomes. 
Wording of the health claim as proposed by the applicant 
The applicant has proposed the following wording for the health claim: “Pre-formed DHA contributes 
to brain development”. 
Specific conditions of use as proposed by the applicant 
The applicant proposed an intake of 250 mg pre-formed DHA/day. The proposed target population is 
infants and children up to 18 years of age. The applicant proposed that all sources of pre-formed DHA 
should be acceptable. 
ASSESSMENT 
1. Characterisation of the food/constituent 
The food that is the subject of the health claim is docosahexaenoic acid (DHA; 22:6 n-3). 
DHA is a well-characterised n-3 long-chain fatty acid that can be quantified in foods by established 
methods. The absorption of DHA is well documented. This evaluation applies to all sources of DHA 
in the specified amounts. 
The Panel considers that the food constituent, DHA, which is the subject of the health claim, is 
sufficiently characterised. 
2. Relevance of the claimed effect to human health 
The claimed effect proposed by the applicant is “contributes to brain development”. The target 
population proposed by the applicant is infants and children up to 18 years of age. 
The Panel considers that contribution to normal brain development is a beneficial physiological effect 
for infants and children. 
DHA and contribution to normal brain development  
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3. Scientific substantiation of the claimed effect 
The applicant performed a literature search in Medline, Embase and the Cochrane database. Details of 
the search strategy, including the search terms, were provided. Studies were included if they were 
randomised, controlled trials in infants and children (up to 18 years of age) free of neurologic or 
behavioural disease or disorder and who had been supplemented, post-natally, with at least 0.3 % pre-
formed DHA from any source and reported measures of basic neurologic function (excludes measures 
of cognition/intelligence/visual performance) related to brain development/cerebral maturation. 
Autopsy reports of human brain tissue content of DHA during various stages of infant/child 
development and studies in primates and piglets on DHA status of brain tissue were also included. 
The applicant identified 14 human studies and 14 animal studies as being pertinent to the health 
claim. 
The Panel has already assessed a claim on DHA and maintenance of normal brain function with a 
favourable outcome (EFSA NDA Panel, 2010a). The target population was the general population. 
The Panel considered that DHA is the major structural lipid in brain tissue and the central nervous 
system, and that the membrane lipids of brain grey matter and the retina contain high concentrations 
of DHA. The Panel noted the well-established role of DHA in brain function (EFSA NDA Panel, 
2010a). 
The Panel considers that the role of DHA in normal brain function applies to all ages, including brain 
development in infants and children. The Panel also notes that the developing brain accumulates large 
amounts of DHA, particularly during the first two years of life (EFSA NDA Panel, 2014), but also 
later and throughout childhood (Carver et al., 2001). Dietary Reference Values for pre-formed DHA 
have been set for infants and children (EFSA NDA Panel, 2010b). 
The Panel concludes that a cause and effect relationship has been established between the 
consumption of DHA and contribution to normal brain development. 
4. Panel’s comments on the proposed wording 
The Panel considers that the following wording reflects the scientific evidence: “DHA contributes to 
normal brain development”. 
5. Conditions and restrictions of use 
The Panel considers that, in order to bear the claim: 
 for older infants (> 6 months of age) and young children below the age of 24 months, foods 
should provide a daily intake of 100 mg DHA in one or more servings (EFSA NDA Panel, 
2010b); 
 for children from 2 to 18 years, foods should provide a daily intake of 250 mg DHA in one or 
more servings. 
Such amounts can be consumed as part of a balanced diet. The target population is infants and 
children up to 18 years. 
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CONCLUSIONS 
On the basis of the data presented, the Panel concludes that: 
 The food constituent, DHA, which is the subject of the health claim, is sufficiently 
characterised. 
 The claimed effect proposed by the applicant is “contributes to brain development”. The 
target population proposed by the applicant is infants and children up to 18 years of age. 
Contribution to normal brain development is a beneficial physiological effect for infants and 
children. 
 A cause and effect relationship has been established between the consumption of DHA and 
contribution to normal brain development. 
 The following wording reflects the scientific evidence: “DHA contributes to normal brain 
development”. 
 In order to bear the claim, foods for older infants (> 6 months of age) and young children 
below the age of 24 months should provide a daily intake of 100 mg DHA in one or more 
servings. Foods for children from 2 to 18 years should provide a daily intake of 250 mg DHA 
in one or more servings. 
DOCUMENTATION PROVIDED TO EFSA 
Health claim application on pre-formed DHA and contribution to normal brain development pursuant 
to Article 14 of Regulation (EC) No 1924/2006 (Claim serial No: 0409_UK). January 2014. 
Submitted by DSM Nutritional Products. 
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ABBREVIATIONS 
DHA docosahexaenoic acid 
